Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002

Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.